First American Trust's CIO tells Reuters' Fred Katayama why he's bullish on Biogen's prospects. The biotech firm's stock surged after its Alzheimer's drug showed positive results in a mid-stage trial.
01:07
01:56
01:42
01:01
01:38
01:13
01:35
01:41
02:02
01:58
01:02
00:54
00:54
02:27
01:48
00:59
01:09
02:19
01:37
01:02
01:23
01:31
00:45
01:04
01:15
01:53
01:02
01:05
01:14
00:50
01:15
02:02
01:02
01:06
01:42
02:43
01:08
01:25
01:57
01:57
01:01
01:41
01:29
00:54
00:19
00:51
01:11
01:06
00:59
01:10
01:05
02:13
02:00
01:01
01:03
01:11
01:02
01:01
02:11
01:14
00:54
01:02
01:17
00:48
00:59
02:19
01:06
00:18
01:51
01:21
01:26
01:33
02:03
01:02
01:57
00:29
01:28
01:21
00:40
01:17
02:05
01:20
01:03
01:16
01:50
00:53
03:21
01:33
01:21
01:22
02:18
01:16
01:42
01:25
01:27
02:27
02:27
01:30
01:51
01:43